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RESEARCH 
COMPARISON OF PERIPHERAL BLOOD ACTIVATED NK CELL 
PERCENTAGE BEFORE AND AFTER INDUCTION PHASE 
CHEMOTHERAPY IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA
(Perbandingan Persentase Sel NK Teraktivasi Darah Tepi Sebelum dan Sesudah 
Kemoterapi Tahap Induksi di Pasien Leukemia Limfoblastik Akut Anak)
Syntia TJ1, Endang Retnowati1, Yetti Hernaningsih1, I Dewa Gede Ugrasena2, Soeprapto Ma’at1
ABSTRAK
Leukemia Limfoblastik Akut (LLA) adalah keganasan sel progenitor limfoid yang berasal dari sumsum tulang dan ditandai proliferasi 
leukosit. Kejadian LLA masih tinggi, sehingga perlu diteliti peran sel NK dalam melawan leukemia. Tujuan penelitian adalah untuk 
mengetahui perbedaan persentase sel NK teraktivasi sebelum dan sesudah pengobatan induksi dan hubungan persentase sel NK teraktivasi 
sebelum pengobatan induksi dengan keluaran kemoterapi pasien LLA anak. Penelitian analitik observasional dengan rancang bangun 
cohort prospektif. Subjek penelitian 27 pasien di Ruang Rawat Inap Hemato-Onkologi Anak RSUD Dr. Soetomo Surabaya, antara bulan 
Maret–Juli 2016. Metode memeriksa flowcytometry menggunakan alat BD FACS CaliburTM reagen Fast Immune CD56FITC/CD69PE/
CD45 Per CP No.katalog.5055879. Analisis statistik dengan uji Wilcoxon Signed Rank dan regresi logistik. Terdapat perbedaan bermakna 
rerata persentase sel NK teraktivasi sebelum pengobatan induksi 0,57% (SB 0,53%) dan sesudahnya 2,01% (SB 1,86%) p=0,000. 
Menunjukkan peningkatan bermakna sel NK teraktivasi sesudah pengobatan induksi. Kenasaban sel NK teraktivasi sebelum pengobatan 
induksi dengan keluaran kemoterapi berkurangnya gejala penyakit (remisi) dan meninggal R=0.723 berarti kenasabannya kuat. 
Peningkatan persentase sel NK teraktivasi sesudah pengobatan induksi disebabkan kerja kemoterapi meningkatkan hasil MICA/B dan 
kerja activating receptors sel NK (NKG2D) yang bersifat sitotoksik yang kuat. Persentase sel NK teraktivasi sebelum pengobatan induksi 
yang rendah disebabkan mekanisme menghilangnya tumor di LLA. Terdapat perbedaan bermakna persentase sel NK teraktivasi sebelum 
dan sesudah pengobatan induksi. Hasilnya dapat menjadi peramal keberhasilan pemberian kemoterapi LLA anak. Persentase sel NK 
teraktivasi sebelum kemoterapi tahap induksi yang tinggi berpengaruh kuat terhadap keluaran kemoterapi berkurangnya gejala penyakit 
dan sebaliknya bila rendah berpengaruh terhadap kemungkinan yang bersangkutan meninggal. Diperlukan hasil jangka panjang sampai 
selesai dalam pengelolaan pemberian pengobatan terkait.
Kata kunci: LLA anak, sel NK teraktivasi, keluaran kemoterapi
ABSTRACT
Acute Lymphoblastic Leukemia (ALL) is a malignancy of the lymphoid progenitor cells from the bone marrow, which characterized 
by leukocytes proliferation. The incidence of ALL is still high, thus the examination about the role of NK cell against leukemia 
cells is needed. The study is aim to know the difference of activated NK cell percentage before and after chemotherapy induction 
and the correlation between activated NK cell percentage before chemotherapy induction with the outcome of chemotherapy in 
ALL by analyzing. This research was an analytical observational study with cohort prospective design. The subjects consist of 27 
patients who were treaded in the Hemato-Oncology Pediatrics Ward at Dr. Soetomo Hospital Surabaya in between March–July 
2016. The examination was done by BD FACS CaliburTM with the reagen from Fast Immune CD56FITC/CD69PE/CD45 Per CP 
No.catalog.5055879 using a flow cytometry. The statistical analysis used Wilcoxon Signed Rank Tes and logistic regression. A 
significant improvement was shown, the mean of activated NK cell percentage before chemotherapy induction was 0.57% (SD 0.53%) 
and after chemotherapy induction was 2.01% (SD 1.86%) with p=0.000. A strong correlation was shown between the activated NK 
cells before chemotherapy induction with an outcome of chemotherapy if high persentage related with remission and low percentage 
related with died (R=0.723). Increased activated NK cell percentage after chemotherapy induction was due to the chemotherapy 
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effect which increased MICA/B production and the role of NK cell activating receptors (NKG2D) having a high cytotoxicity. A 
significant difference of activated NK cell percentage before and after chemotherapy induction was shown. The results can be used 
as a predictor of successful chemotherapy and as a prognostic factor. Activated NK cell percentage before chemotherapy strongly 
influenced the outcome of chemotherapy, if high percentage related with remission and low percentage related with the death. So 
in this case a long-term observation until complete chemotherapy management is needed.
Key words: ALL, activated NK cell, outcome of chemotherapy
INTRODUCTION
Acute Lymphoblastic Leukemia (ALL) is a 
malignancy of lymphoid progenitor cells derived from 
bone marrow leukocytes and characterized by the 
proliferation of leukocytes and the manifestation of 
abnormal cells in the peripheral blood.1 The peak age 
of incidence is between 3–5 years. Acute lymphoblastic 
leukemia is more common in male than female.2 The 
incidence of the disease in the United States based on 
The Surveillance, Epidemiology and End Result (SEER, 
2006) Program of National Cancer Institute provides 
information on ALL statistics was ±3,930 new cases 
each year.3 Acute Lymphoblastic Leukemia in Indonesia 
was ±2.5–4.0 per 100,000 children. The new cases 
of ALL in Indonesia was ±2000 to 2300 each year.4 
The new cases of ALL children at Dr. Soetomo Hospital 
Surabaya in 2006 were as many as 82 children; 
remission 33 patients (48.5%), non-remission 10 
patients (14.7%) and 25 patients died (36.8%).5 The 
high rate of resistance of drugs around 9.3 cases/106 
children per year, remains a significant problem.6 ALL 
patients who died is still high, one of which caused by 
the failure of the treatment. The differences response 
of chemotherapy influencies to patients outcomes.6
This study observed the immunity cellular response 
especially role of NK cell in ALL pediatric of this to 
analyze that there were correlated with the outcome 
of chemotherapy induction phase, because of this 
treatment was aimed to eradicatie about 99% leukemia 
cells and return to the normal hematopoiesis system. 
The chemotherapy induction phase was administered 
for six (6) weeks. The chemotherapy outcome was 
determined by a percentage of lymphoblasts in 
the bone marrow by microscopic morphological 
examination induction therapy regiment based on 
the BFM/COG (The Berlin-Frankfurt - Munster/a 
Children’s Oncology Group) included vincristine, 
anthracycline, corticosteroid and L-asparaginase.7
The NK cell has an important component role as 
an effector mechanism against leukemia cells with 
spontaneuos cytotoxicity to all various types of cell 
targets in the eliminate on of cancer by inhibiting cell 
proliferation and angiogenesis, triggering apoptosis, 
stimulating adaptive immune system and increased 
processing as well as antigen presentation.7 The 
role of NK cells in hematological malignancies was 
first published by Costelloetal,8 that there was a 
significant increase of NK cells activated in patients 
with hematological malignancies after getting 
chemotherapy.8 Following this, another study which 
made the NK cell as a candidate for a new strategy of 
immunotherapy. So another study is needed to compare 
the activated percentage of NK cells (CD56+CD69+) 
after chemotherapy induction phase associated with 
the patients outcome at this time has not been studied 
at Dr. Soetomo Hospital Surabaya.9 This study will 
helps the clinicians overcome the problem in the 
immunity of patients and improve the treatment 
success rate of ALL patients. The aim of the study was 
to know the difference of activated NK cell percentage 
before and after chemotherapy induction and the 
correlation between activated NK cell percentage 
before chemotherapy induction with outcome of 
chemotherapy in ALL. The benefits of this study were 
to provide the examination of NK cells that could be 
used as a predictor of successful drug chemotherapy, 
that determining the prognosis of pediatric ALL and to 
provide the suggestion for the clinicians to develop of 
NK cells as an immunotherapy.
METHODS
This type of study was an analytical observational 
study with a cohort prospective design. The sampling 
was done in the Hemato-Oncology Pediatric Ward at 
Dr. Soetomo Hospital Surabaya and the processing 
of the samples were carried out in the Laboratory of 
Clinical Pathology, Dr. Soetomo Hospital Surabaya 
between March–July 2016. The calculation of the 
sample size was at least 15 people. The inclusion 
criteria were ALL patients aged between 1 month-8 
years newly diagnosed and who received the same 
protocol treatment of chemotherapy and the parents/
guardians agreed to participate in this study. The 
exclusion criteria was ALL patients who have been 
treated with steroids and cytostatics earlier. And the 
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drop out criteria were patients who withdrew from the 
study. The statistical analysis used Wilcoxon Signed 
Rank Tes to comparing the activated percentage NK 
cells and logistic regression to the related activated NK 
cells with chemotherapy outcomes.
RESULTS AND DISCUSSION
The study involved 30 ALL pediatric patients before 
the induction therapy and after the induction phase of 
remission obtained in 19 patients, three (3) patients 
were dropped out and eight (8) patients died. The 
total study subjects were 27 patients, mostly male 18 
children (66.7%) and females 9 children (33.3%). The 
age of patients were about 1–14 years, the mean and 
standard deviation were of 6.59 years and 4.34 years 
(see Table 1).
The most incidence was ≤ 5 years of age and 
the ratio of males and females was 2 : 1, according 
to Widiaskara in 20055 males suffer more of ALL. 
In males and females can undergo chromosomal 
translocations in leukemia resulting in excessive de 
regulation of gene expression or form a new gene 
fusion, aneuploidy and specific gene mutations. A factor 
which affect the prognosis of males patients more 
worse than females, is that incidence of Philadelphia 
translocation is often found in males. Another factor 
is the difference metabolism of lymphoblast in the 
maintenance phase of chemotherapy regimens among 
male with female. This study showed that the largest 
age group of the first time was diagnosed as ALL was 
≤ 5 years, as according Widiaskara study.5 Age is a 
significant prognostic factor in ALL pediatric patients. 
In patients with aged ≤ 5 years or age between 2~5 
years showed that the survival rate was two times 
greater than the comparation to the age ≤2 years or 
≥10 years.
The results of hemoglobin levels, number of 
leukocytes and platelet counts in 27 patients on 
examination before and after induction phase can be 
seen in Table 2.
The mean of hemoglobin levels before induction 
therapy was 6.98 (g/dL) and the mean after that was 
8.06 (g/dL). So that the average increased, but not 
significantly different (p=0.449). Presumably because 
leukemic cells accumulation in the bone marrow lead 
to disruption of blood cell formation and the effects 
of induction chemotherapy drug suppressing the 
growth of stem cells and induced apoptosis of young 
hematopoietic cells.
The mean number of leucocytes before induction 
therapy was 98,993 (×106/mL), while the average 
number of leucocytes after induction therapy was 
4,116 (×106/mL), so that the average decreased 
significantly (p=0.000). The children with the 
number of leukocytes ≥50,000 (×106/mL) were at 
a high risk category for experienced non-remission, 
relapse and died. The children with high leukocytes 
early in the disease before induction therapy, have 
a high progressive proliferation of blast cells. Acute 
lymphoblastic leukemia ediatric patients with leukocyte 
count ≥50,000 (×106/mL) are major risk factor for 
Tumor Lysis Syndrome (TLS) and infection. Tumor 
lysis syndrome greatest risk was during the induction 
phase of chemotherapy for rapid tumor destruction and 
excessive at the same time.
The results mean of platelets after induction therapy 
was 134,037 (×103/mL), whereas the mean platelet 
count prior to induction therapy was 69,409 (×103/
mL) so that the average had increased significantly 
(p=0.001). From the 27 ALL patients studied only 19 
patients had complete data for the activated NK cells 
percentage before and after the induction phase (see 
Table 3).
Table 1. The characteristics of the subjects
The sample characteristics Frequency %
Gender
Males 18 66.7%
Females 9 33.3%
Age (year)
The average ± SD
<5 year
5–10 year
>10 year
6.59 ± 4.34
14
5
8
–
51.9%
18.5%
29.6%
Range (min - max) 1 s/d 14 –
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Table 2. The profile of hemoglobin levels, number of leucocytes and platelets
Data
 Before induction phase After induction phase 
Range
The average ±SD
Range
The average ±SD
p
Hemoglobin 
(g/dL)
4.20–10.20
6.98±1.68
0.0–14.40
8.06±5.39
0.449
Leucocytes 
(×106/μL)
1850–595000
98 993±136569
0–9900
4.116±3.171
0.000 *
Platelets
(×103/μL)
30000–204000
69 409±40988
0–230000
134 037±90506
0.001
Tabel 3. The number of activated NK cells before and after induction therapy
Time of examination N
Activated NK cells percentage (%)
x SD Minimum Maximum
Before induction therapy 27 0.45 0.48 0.04 2.13
After induction therapy 19 2.01 1.86 0.21 6.06
Table 4. The normality test of the activation of NK cells percentage
Data Group Value of Shapiro Wilks p-value Information
Activated NK cells percentage (%) Pre induction 0.705 0.000 Not normally
Post induction 0.766 0.000 Not normally
Table 5. The comparison of the activated NK cell percentage before and after chemotherapy induction
Time of examination n
Activated NK cells percentage (%)
p
x SD Minimum Maximum
Before induction therapy 19 0.57 0.53 0.07 2.13
0.000 *
After induction therapy 19 2.01 1.86 0.21 6.06
* Significant at = 0.05 (Wilcoxon Signed Rank Test)
Normality test of comparing to difference of 
the activated NK cell percentage before and after 
chemotherapy induction study by Shapiro Wilk, 
showed that the data obtained were not normally 
distributed (see Table 4).
The comparison analysis of the activated NK cells 
percentage before and after chemotherapy induction 
was done by using Wilcoxon Signed Rank Test, 
p=0.000. The significant differences of activated 
NK cell percentage before and after chemotherapy 
induction were shown (see Table 5).
The activated percentage NK cells after 
chemotherapy induction phase increased significantly 
compared to before induction therapy. The increased 
of activated NK cell (CD56+CD69+) percentage 
after chemotherapy induction phase can be used as 
a predictor of successful drug chemotherapy in ALL 
children. The theories of Burmester and Pezzutto14 
about the effect of chemotherapy on the activity of NK 
cells, showed that chemotherapy can kill cancer cells to 
become debris that act as cancer antigen and captured 
by APC. Cancer antigen will stimulate the activity 
of effector cells, including NK cells, macrophages, 
dendritic cells, TCD4 and TCD8 cytotoxic cells. Another 
mechanism of action of chemotherapy against NK 
cells was by increasing DNAM ligand-1 regulation and 
increasing employment activating receptors (NKG2D) 
which have a strong cytotoxicity.
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The study carried out by Shi16 suggested that 
the group of demethylating agents (azacitidine and 
decitabine) and members of the immune-modulatory 
drugs (thalidomide and lenalidomide) improved 
recognition of activating receptors (NKG2D and 
NKp46) against the ligands. The histone deacetylase 
inhibitors (trichostatin) group increased the production 
of MICA/B,ULBP-2 is ligand of activating receptors 
(NKG2D). The group of histamine dihydrochloride 
All-trans retinoic acid monoclonal antibody 
(Rituximab) increased the affinity Fc receptor 
(FcgRIII) through ADCC process against cancer 
cells during recognition causing degranulation by 
releasing perforin protein cytolytic and granzyme 
B, so the target cell would undergo apoptosis and 
necrosis. Bortezomib (proteasome inhibitor) caused 
the degradation of proteins and increased expression 
of NKG2D. Dounorubicin and doxorubicin increased 
the production of MICA/B, ULPBI-3, PVR, Nectin-2 
and increased expression of DNAM-IL Group Tyrosine 
kinase inhibitor (Imatinib) also served to increase 
activating the expression of NKG2Dreceptors.
On examination of 27 patients obtained results with 
chemotherapy outcomes as follows:
Table 6. Distribution of chemotherapy outcome
Outcome Frequency %
Remission 19 70.4
Died 8 29.6
The result of chemotherapy outcome were 19 
patients (70.4%) in remission and 8 patients (29.6%) 
died.
The significant difference of the activated NK cell 
percentage before chemotherapy induction related 
with the remission outcome compared to those who 
died was shown (p<0.05). 
The regression logistic analysis showed that 
activated NK cells percentage before induction therapy 
strongly influenced the chemotherapy outcome 
(p=0.027). The magnitude of correlation between 
activated NK cells percentage before chemotherapy 
induction phase with chemotherapy outcomes 
was remission and deat obtained from regression 
coefficient (R)=√ 0523=0723, which means a strong 
correlation category. Patients with the activated NK 
cells percentage before chemotherapy induction 
phase which has a high chances of remission and 
patients with the activated NK cells percentage before 
chemotherapy induction phase has a low result. So the 
chemotherapy outcome was death, these results could 
be used as prognostic determinant in ALL pediatric 
patients.
There was a correlation between the activated NK 
cells percentage were higher on before chemotherapy 
induction phase has the chance of remission, can give 
the clinician’s suggestion on the development of NK 
cells as an immunotherapy. According to Burke et al.9 
strategy to increase NK cell activity against leukemia 
cells by increasing endogenous activation of NK cells 
and how adoptive transfer. Increased endogenous 
activation of NK cells by way of an adjuvant such 
as TLR ligand aims to redistribute endogenous cells 
NK cells from the related population in the blood 
(CD56-CD16+) are strong cytotoxins to lymph nodes 
that populations of NK cells are cytotoxins weak 
(CD56+CD16-). The provision of chemotherapy also 
served to increase the activation of endogenous NK 
cells as mephalan, doxorubicin, orbortezomib to 
improve ligands regulation of NKG2D on leukemia.
In this study, there were eight (8) patients ALL who 
died (29.6%) possible due to higher risk infection and 
decrease the immune system. This study showed that 
patients with activated NK cell percentage were low 
prior to induction therapy greatly affected the outcome 
of chemotherapy died (r =0.723). In the research of 
Baier et al.,15 explained that the mechanism of tumor 
occurs ALL escape. This mechanism affects the 
decrease in production of MHC class 1 chain-related 
protein A/B (MICA/B), thereby weakening the signal 
in triggering caspase so DNA target cells did not 
undergo apoptosis. Other tumor escape mechanism 
Table 7.  The comparison result of activated NK cell percentage before chemotherapy induction 
related with chemotherapy outcome remission and died 
Outcome n
Activated NK cells percentage (%)
p
x SD Minimum Maximum
Remission 19 0.57 0.53 0.07 2.13
0.002 *
Died 8 0.16 0.08 0.04 0.25
* Significant at = 0.05 (Mann-Whitney Test)
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is a mutation of the gene Major Histocompatibility 
Complex class 1 (MHC class 1) thereby disrupting 
the regulation of MHC class 1 result able to recognize 
inhibitory NK cell receptors that become active and 
target cells are not killed. In addition ALL remove the 
tumor derived soluble factor (TDSF) which contribute 
to triggering the formation of an immunosuppressive 
compound is VGEF, IL-10, TGF- and prostaglandin E. 
TDSF significantly inhibit cytotoxicity NK cells.
Other factors are the resistance to chemotherapy is 
a phenomenon when tumor cells become insensitive to 
chemotherapy drugs. The mechanism of chemotherapy 
resistance in general to include cancer; eff lux 
pump chemotherapy drugs due to overexpression 
of trans-membrane transporter protein (P-gp); the 
enzyme polymorphism pemetabolisme drugs such 
as enzyme thymidylate synthase polymorphisms 
and metilentetrahidrofolat reductase; defects in the 
apoptotic pathway because overexpression of anti-
apoptotic proteins (Bcl-2) and a defect in the pro-
survival pathway through the activation of NF-Kb.7 
specific mechanisms in ALL include the existence of 
a set of gene expression associated with; resistance 
to a single chemotherapeutic agent; cross-resistance 
and minimal residual disease (MRD). The results of 
examination of the percentage of activated NK cells 
(CD56 + CD69 +) in healthy people were as follows:
Table 8.  The result of analysis regression logistic about influencing the activated of 
percentage NK cells before induction therapy related chemotherapy outcome
Variable B P R2
NK cells pre induction -13.11 0.027 *0.523
Constant 2.43 0.069
* Significant at = 0.05
The activated NK cells percentage (CD56+CD69+) 
in 6 healthy individuals ranged from 0.12 to 0.67% 
with an average of 0.42% and a standard deviation of 
0.16%. The results of the examination activated NK 
cells percentage (CD56+CD69+) is low this indicated 
the absence of stimulation of NK cell activation in 
healthy people. The purpose of examination activated 
NK cells percentage in healthy people to determine 
the range normal value of NK cells. In accordance 
to the study carried out by Johanis19, which shown 
that the normal range of activated NK cells obtained 
by examining 10 healthy individuals ranges between 
0.95–1.67%, with the average of 0.50% and a standard 
deviation of 0.49%.
CONCLUSIONS AND SUGGESTIONS
The study conclusions based on the results and 
discussion are as follows: There are significant 
differences in the activated NK cells percentage before 
and after chemotherapy induction phase. These 
results can be used as a predictor of successful drug 
chemotherapy in ALL pediatric patients; The activated 
NK cells percentage before chemotherapy induction 
phase has astrongly influenced to chemotherapy 
outcome. Patients with the activated NK cells 
percentage before chemotherapy induction phase 
Table 9.  The activated NK cells percentage in normal patients
No Name Age The activated NK cells percentage (%)
1. An.Ag 12 0.47
2. An.F 11 0.12
3. An.Al 13 0.37
4. An.J 11 0.51
5. An.S 12 0.38
6. An.T 13 0.67
Mean 0.42
SD 0.16
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which has a high result, so the chemotherapy outcome 
was remission and patients with the activated NK cells 
percentage before chemotherapy induction phase has a 
low result so the chemotherapy outcome was death.
Those results could be used as prognosis 
determinant in ALL pediatric patients. It is suggested 
a long-term studies should be done to complete the 
management of chemotherapy and necessary to 
be done studies about activated NK cells in vitro by 
culture Peripheral Blood Mononuclear Cell (PBMC) for 
better results.
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